Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | This year at our Brain Tumour conference you can hear keynote lectures from Arnold Kriegstein (University of California, San Francisco) and Karen Vousden (The Francis Crick Institute). Arnold will share insights into the role of neural stem cells in human brain development and glioblastoma, and Karen will delve into diet, metabolism and cancer progression.
Join us in London on 24 – 26 September to hear about novel tools, emerging ideas and the latest developments in the field alongside a community of international researchers.
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
Congratulations to our latest grant awardees |
| Meet the latest grant awardees selected by our Discovery Research Committee:
Linda Wooldridge was selected for a new Programme Award, while Peter McHugh, Christopher Schofield, Jussi Taipale and Pascal Meier received renewing Programme Awards.
Luca Magnani, Nicholas McGranahan, Audrey Gerard and Helen Rowe received Programme Foundation Awards, while Campbell Roxburgh, Joanne Edwards and Emiliano Spezi received Multidisciplinary Project Awards. Ricardo Fernandes received a Cancer Immunology Project Award.
Oscar Ces and Charlotte Bevan received a Cancer Research UK & Prostate Cancer UK Innovation Award co-funded by us and Prostate Cancer UK. |
| | |
|
|
|
Call for evidence - UK visa & immigration system and impact on protected characteristics |
| Following the government announcements on updated to immigration policy, UKRI released an updated Global Mobility evidence report which highlighted significant gaps in its understanding of global researcher mobility.
To address one of these gaps, UKRI has commissioned EDI Caucus to look into the diversity of globally mobile researchers and the impact of UK immigration policy on groups with protected characteristics, and they need your help.
If you have unpublished research or firsthand experience of supporting or hiring individuals applying for visas in the last 5 years, share your insights to the call for evidence.
They are also keen to hear from those who have considered relocating to the UK for work in the research and innovation sector but were deterred by visa and immigration challenges.
|
| | |
|
|
|
The case for protecting research time in the NHS |
| Thank you to those of you who inputted into our Clinical Research Workforce Survey. We wanted to understand whether it’s become easier or more challenging to deliver clinical research, and what the top priorities for policymakers should be in this space, we received over 600 responses.
Almost three quarters of respondents felt that it’s becoming harder to deliver research in a timely manner. Top barriers reported include the wider NHS pressures, staff vacancies, bureaucracy setting up studies and a weak NHS research culture. Worryingly, nearly one third of surveyed clinical research staff also said they would be more likely to leave UK-based clinical research in the next 5 years based on the recent developments in the sector.
The findings from this report have, and will continue to, inform our policy priorities and activities, including the recommendations in our Longer, Better Lives manifesto and programme for government. We have also published an article which explores the findings of this report, commenting on actions the Goverment could take to re-establish the UK's position as a global leader in clinical research. |
| | |
|
|
|
| | | | | Aleta Biotherapeutics and our Centre for Drug Development have dosed the first patient in a Phase 1/2 clinical trial of Aleta’s CAR T-cell engager.
This pioneering therapy targets patients with relapsed or refractory blood cancer, facing disease progression following CAR T-cell therapy.
Led by Sridhar Chaganti, Chief Investigator at University Hospitals Birmingham NHS Foundation Trust, the trial will assess the safety, dosage, pharmacology, and early efficacy of Aleta’s agent.
This collaboration capitalises on the Centre for Drug Development's expertise in designing clinical trials for novel anti-cancer agents. | | |
| | | | | | | Join the Panacea Stars programme to access an eight-week training designed to bring your business idea to life.
Led by industry and academic leaders, this programme offers tailored workshops, networking opportunities, and occasional workspace at the Panacea Innovation Centre with a chance to secure a £100k non-dilutive prize. | | |
|
|---|
|
|
|
|
We’d love to hear about your research... |
| Are you preparing a Cancer Research UK-funded research paper for publication? If so, we’d love to hear about it.
You can let us know about pending publications via our manuscript notification form. We will treat all information confidentially and won’t use any without consulting you first.
This will help us plan our communications and better talk to our supporters about the work that their donations help fund. |
| | |
|
|
|
What did you think of this email? |
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
